# Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
Canonical URL: https://biopharmsignal.com/news/ASND/ascendis-to-showcase-advances-in-treatment-of-rare-endocrine-diseases-at-endo-2026
Ticker: ASND
Company: Ascendis Pharma
Source: Ascendis Pharma
Published: 2026-06-25 13:46 EST
Original Source URL: https://investors.ascendispharma.com
## Summary

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and

## Article Body
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and
## Recent Company News
- 2026-06-30 12:30 EST — [Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial](https://biopharmsignal.com/news/ASND/children-with-achondroplasia-treated-with-transcon-cnp-showed-continued-improvem-93d02f62) — Source: Ascendis Pharma
- 2026-06-26 20:01 EST — [Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®](https://biopharmsignal.com/news/ASND/ascendis-joins-multiple-russell-u-s-indexes-including-the-russell-3000-russell-1-d1ad8aa7) — Source: Ascendis Pharma
- 2026-06-25 20:01 EST — [Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026](https://biopharmsignal.com/news/ASND/ascendis-to-showcase-advances-in-treatment-of-achondroplasia-at-iccbh-2026-cf687b9b) — Source: Ascendis Pharma
- 2026-06-25 13:46 EST — [Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism](https://biopharmsignal.com/news/ASND/phase-3-data-show-transconr-pth-replicated-systemic-actions-of-endogenous-pth-through-week-182-in-adults-with-hypoparathyroidism) — Source: Ascendis Pharma
- 2026-06-25 13:46 EST — [5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism](https://biopharmsignal.com/news/ASND/5-year-phase-2-data-show-transconr-pth-replicated-systemic-actions-of-endogenous-pth-in-adults-with-hypoparathyroidism) — Source: Ascendis Pharma
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)